Case Study: Critical Comparator Rescue: Supplying 1,000 Packs of EU-Origin PD-1 Immune Checkpoint Inhibitor for Phase 3 Oncology Trial
A US-based clinical-stage biotechnology company, actively engaged in the development of next-generation immuno-oncology therapies, was preparing for a multisite Phase 3 interventional clinical trial across several European Union member states. The trial involved a therapeutic regimen where a PD-1 immune checkpoint inhibitor widely used in oncology was utilized as a comparator in one of the…
